Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
about
Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer modelUntangling the Manganese-α-Synuclein WebStaging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathyNoradrenergic Modulation of Cognition in Health and Disease.Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.Protein disorder in the human diseasome: unfoldomics of human genetic diseases.Unfoldomics of human diseases: linking protein intrinsic disorder with diseasesThe Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative DiseasesTau aggregation into fibrillar polymers: taupathies.Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction.Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.The muscle protein dysferlin accumulates in the Alzheimer brain.Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.Familial encephalopathy with neuroserpin inclusion bodiesA novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression.Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice.Tau phosphorylation and aggregation in Alzheimer's disease pathology.Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domainTau phosphorylation, aggregation, and cell toxicityDecreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease.Amyloidogenesis of natively unfolded proteins.Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat.DISCopathies: brain disorders related to DISC1 dysfunction.Inflammation in the early stages of neurodegenerative pathologySubventricular zone under the neuroinflammatory stress and Parkinson's disease.Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases.Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration.The function of α-synuclein.Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases.Posttranslational Modifications and Clearing of α-Synuclein Aggregates in YeastTau oligomers impair artificial membrane integrity and cellular viability.Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism.Three-dimensional structure of the lithostathine protofibril, a protein involved in Alzheimer's disease.Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells.Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.[(18)F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP.
P2860
Q24305472-D6B13E6E-4D64-425B-824E-E7FA4CF33462Q26740340-F005370E-F1FA-4FBA-B215-507B3B5FF034Q28345670-A38AA54F-A77F-4900-A560-165A1D89456FQ30354689-7476A60E-E9C4-42AF-BCC5-6A1AAAD2AB6AQ30476254-8B5389FB-DC04-47AF-A388-161C9BF7E535Q33470625-2B992872-04E7-47AC-9F03-B262DD685ABDQ33481211-37320969-7996-4AAC-A47C-D5222A26B3D9Q33481254-22C01E68-1DF3-4543-BFB5-23C84A7595D6Q33692255-0A8A54F3-2BB0-4C54-BF0C-EFD9244EB035Q33957159-EA934689-5A0F-4720-BF3C-390228E7FBB7Q34105358-8681F9F1-398B-4F7D-ACFA-D715465B8610Q34556945-8539B216-7EF6-4FD3-A666-18D908B9C9D5Q34648491-4B470FAD-E7BA-477A-95BA-D271E675D5E5Q35065979-191081BE-8588-434E-AF09-2D289835EB17Q35230012-AD93BC52-F64F-4FAD-84B1-D17355CE55E3Q35597118-9764DDC0-7617-448F-9D6C-FC0AB161DE01Q35750194-1BBE2BF5-116F-4A5D-B4FC-47E2FCF39477Q35840376-CE93C0D2-74CC-46D4-BD9B-E15CAA1FA93EQ35903351-1752446E-59B1-47FD-BC0D-9BD6950E9A30Q36418199-E12DDE1B-8D67-4DD3-8209-BF310081C63FQ36527246-F1454E66-3EDD-4C7F-905C-816AC3B6AC67Q36626384-772A9841-1FE4-4AF9-B3C6-3CB6F0306AAEQ36746491-4320FD21-9ABD-43EB-B7A1-32D8A4094F41Q37184755-0DEBBFD1-2D57-4D53-A12C-AD73072F1FC6Q37386416-A2335F8B-8F0F-41B9-B375-E15625B60ED4Q37732176-622FFF24-22FF-4171-AEC3-06BB104C8B8EQ37912590-67BA0732-0FD9-46FD-B4F8-506D2E2B7726Q37970601-ABB439E2-F68A-4C54-BEA4-1C8BDCF48B12Q38037524-DECFDC53-9658-4556-95FA-F495BED27FB2Q38039857-287BE602-9B08-4F1E-8A7C-669650B9987FQ38139561-B63BDC27-467B-42FF-AE3D-9FDFC4ACB06FQ38185934-8A68CB66-FCB0-467B-861E-5B9A9BA34F29Q38444052-3F9E267A-BFDA-4169-B2F7-7919107ECD88Q39248841-1AA40685-292C-488D-9632-9D05D03AA45FQ39297100-DDC8BA8C-DB87-4C9F-81B1-63638A09E125Q39645458-F3F8983E-69BE-4A6A-A04E-BF128A5AC2BEQ39670506-D4A74EFC-C173-4505-A52E-B2A84DF3E8F5Q42521775-02F26621-AFBB-44C7-9B6A-C8079828A518Q42711308-834ABE94-8932-47A5-A73E-CECBDB6E6526Q47627080-0328F267-15F3-4777-8D3D-47AFA67B8C41
P2860
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Filamentous nerve cell inclusi ...... s and alpha-synucleinopathies.
@ast
Filamentous nerve cell inclusi ...... s and alpha-synucleinopathies.
@en
type
label
Filamentous nerve cell inclusi ...... s and alpha-synucleinopathies.
@ast
Filamentous nerve cell inclusi ...... s and alpha-synucleinopathies.
@en
prefLabel
Filamentous nerve cell inclusi ...... s and alpha-synucleinopathies.
@ast
Filamentous nerve cell inclusi ...... s and alpha-synucleinopathies.
@en
P2860
P356
P1476
Filamentous nerve cell inclusi ...... s and alpha-synucleinopathies.
@en
P2093
P2860
P304
P356
10.1098/RSTB.1999.0466
P407
P577
1999-06-01T00:00:00Z